Tirzepatide 60mg TR60

Semaglutide 5mg,Semaglutide,Semaglutide peptide,peptide,lyophilized powder,research peptide,peptide vial,peptide raw material,factory supply,research grade peptide

Bulk Drug Intermediates

Dual agonist — GIPR, GLP-1R

FDA-approved (Mounjaro / Zepbound)

Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.

0.934 nM

0.0224 nM

Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI

NCT03954834; NCT03987919; NCT03882970; NCT03730662; NCT04039503

Mounjaro, Zepbound (approved 2022-05-13)

CHEMBL4297839

DB15171

D11360

PubChem

NEJM: Frias et al. (2021) — SURPASS-2; FDA: Mounjaro (NDA 215866)

Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.